Adocia Announces Half Year Report on Adocia’s Liquidity Agreement With Kepler Capital Markets
Under the liquidity agreement entrusted by Adocia (Paris:ADOC) to Kepler Capital Markets, the following resources were listed on the liquidity account on December 31, 2020:
- 30,533 shares
- € 104,644.60
- Number of executions on buy side on semester: 318
- Number of executions on sell side on semester: 355
- Traded volume on buy side on semester: 45,143 shares for € 353,656.52
- Traded volume on sell side on semester: 47,151 shares for € 374,968.20
As a reminder:
• the following resources appeared on the last half year statement on June 30, 2020 on the liquidity account:
- 32,541 shares
- € 83,332.92
• the following resources appeared on the liquidity account when the activity started:
- 15,026 shares
- € 300,000.00
The liquidity agreement complies with AMF Decision n° 2018-01 dated 2nd July 2018, introducing liquidity agreements on equity securities as permitted market practice
Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of therapeutic proteins and peptides for the treatment of diabetes and metabolic diseases. In the diabetes field, Adocia’s portfolio of injectable treatments is among the largest and most differentiated of the industry, featuring five clinical-stage products and three products in preclinical-stage. The proprietary BioChaperone technological platform is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. Adocia customizes BioChaperone to each protein for a given application.
Adocia’s clinical pipeline includes four novel insulin formulations for prandial treatment of diabetes: two ultra-rapid formulations of insulin analog lispro (BioChaperone Lispro U100 and U200), a combination of basal insulin glargine and rapid-acting insulin lispro (BioChaperone Combo) and one combination of a prandial insulin with amylin analog pramlintide M1Pram. The clinical pipeline also includes an aqueous formulation of human glucagon (BioChaperone Glucagon) for the treatment of hypoglycemia.
Adocia preclinical pipeline includes three bi-hormonal products: two combinations of rapid human insulin analogues and Pramlintide (BioChaperone LisPram andBioChaperone AsPram) and a combination of insulin glargine with Liraglutide (BioChaperone GlaLira) for the treatment of diabetes.
Adocia recently added a fourth program in preclinical with the development of a hydrogel scaffold for cell therapy in the treatment of type 1 diabetes. A first patent has been filed.
This press release contains certain forward-looking statements concerning Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the “Risk Factors” section of the Reference Document filed with the French Autorité des marchés financiers on April 22, 2020 (a copy of which is available at www.adocia.com) and to the development of economic conditions financial markets and the markets in which Adocia operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not currently considered material by Adocia. The occurrence of all or part of such risks could cause actual results, financial conditions, performance, or achievements of Adocia to be materially different from such forward-looking statements. This press release and the information contained herein do not constitute an offer to sell or the solicitation of an offer to buy Adocia shares in any jurisdiction.
ADOCIA Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de